Country: Kanada
Bahasa: Inggeris
Sumber: Health Canada
FLUDEOXYGLUCOSE 18F
CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION
V09IX04
FLUDEOXYGLUCOSE (18F)
453GBQ
SOLUTION
FLUDEOXYGLUCOSE 18F 453GBQ
INTRAVENOUS
100
Schedule C
ROENTGENOGRAPHY
Active ingredient group (AIG) number: 0152591020; AHFS: 36:68.00
APPROVED
2010-07-02
_ _ _GLUCOVISION_ _®_ _ ([F-18]-Fludeoxyglucose (FDG) Injection) _ _Page 1 of 25_ PRODUCT MONOGRAPH GLUCOVISION ® [F-18]-Fludeoxyglucose (FDG) Injection [F-18]-FDG Phosphate, 1 - 540 GBq per batch at EOS [F-18]-FDG Citrate, 1 - 453 GBq per batch at EOS Diagnostic Radiopharmaceutical Centre for Probe Development and Commercialization (CPDC) 1280 Main Street West NRB A316 Hamilton ON L8S 4K1 www.imagingprobes.ca _ _ Submission Control No: 195237 Date of Approval: August 16, 2016 Date of Revision: August 10, 2016 _ _ _GLUCOVISION_ _®_ _ ([F-18]-Fludeoxyglucose (FDG) Injection) _ _Page 2 of 25_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .......................................................... 3 SUMMARY PRODUCT INFORMATION......................................................................... 3 DESCRIPTION .................................................................................................................... 3 INDICATIONS AND CLINICAL USE .............................................................................. 4 CONTRAINDICATIONS .................................................................................................... 5 WARNINGS AND PRECAUTIONS .................................................................................. 5 ADVERSE REACTIONS .................................................................................................... 7 DRUG INTERACTIONS .................................................................................................... 8 DOSAGE AND ADMINISTRATION ................................................................................ 9 RADIATION DOSIMETRY ............................................................................................. 10 OVERDOSAGE ................................................................................................................. 12 ACTION AND CLINICAL PHARMACOLOGY ............................................................. 12 STORAGE AND STABILITY ..................................... Baca dokumen lengkap